Cited by 300Diabetes Treatment and ManagementRegulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Open access

Mannucci, Edoardo, Ognibene, Agostino, Cremasco, Francesco, Bardini, Gianluca, Mencucci, Antonella, Pierazzuoli, Enrica, Ciani, Silvia, Messeri, Gianni, Rotella, Carlo M.·2001·Diabetes Care

DOI 10.2337/diacare.24.3.489

Open this paper in CoChat — free account

Abstract

OBJECTIVE—To evaluate the effects of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels. RESEARCH DESIGN AND METHODS—A total of 10 obese nondiabetic male patients were studied before and after a 14-day treatment with 2,550 mg/day metformin and were compared with 10 untreated obese control subjects. On days 0 and 15, leptin and GLP-1(7–36)amide/(7–37) levels were assessed before and after an oral glucose load during a euglycemic hyperinsulinemic clamp to avoid the interference of variations of insulinemia and glycemia on GLP-1 and leptin secretion. The effects of metformin on GLP-1(7–36)amide degradation in human plasma and in a buffer solution containing dipeptidyl peptidase IV (DPP-IV) were also studied. RESULTS—Leptin levels were not affected by the oral glucose load, and they were not modified after metformin treatment. Metformin induced a significant (P < 0.05) increase of GLP-1(7–36)amide/(7–37) at 30 and 60 min after the oral glucose load (63.8 ± 29.0 vs. 50.3 ± 15.6 pmol/l and 75.8 ± 35.4 vs. 46.9 ± 20.0 pmol/l, respectively), without affecting baseline GLP-1 levels. No variations of GLP-1 levels were observed in the control group. In pooled human plasma, metformin (0.1–0.5 μg/ml) significantly inhibited degradation of GLP-1(7–36)amide after a 30-min incubation at 37°C; similar results were obtained in a buffer solution containing DPP-IV. CONCLUSIONS—Metformin significantly increases GLP-1 levels after an oral glucose load in obese nondiabetic subjects; this effect could be due to an inhibition of GLP-1 degradation.

Integrity signals

Registry

Crossref · 10.2337/diacare.24.3.489

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Biguanides and NIDDM
Bailey, C. J. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.755 · Cited by 593
Glucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 577
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Metformin Decreases Food Consumption and Induces Weight Loss in Subjects with Obesity with Type II Non‐Insulin‐Dependent Diabetes
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus
Mäkimattila, S., Nikkilä, K., & Yki‐Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 201–297 of 297

The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus
Nguyen, T., Gong, M., Wen, S., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4727390 · Cited by 13
Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study
Hashimoto, Y., Tanaka, M., Okada, H., Mistuhashi, K., Kimura, T., Kitagawa, N., Fukuda, T., Majima, S., Fukuda, Y., Tanaka, Y., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0786-4 · Cited by 12
Differential increments of basal glucagon‐like‐1 peptide concentration among SLC 47A1 rs2289669 genotypes were associated with inter‐individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes
Liang, H., Xu, W., Zhou, L., Yang, W., & Weng, J. (2017) · Diabetic Medicine · doi:10.1111/dme.13351 · Cited by 12
Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study
Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674308 · Cited by 12
Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add‐ons to metformin: A retrospective cohort database study
Bloomgarden, Z. T., Tunceli, K., Liu, J., Brodovicz, K. G., Mavros, P., Engel, S. S., Radican, L., Chen, Y., Rajpathak, S. N., Qiu, Y., et al. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12461 · Cited by 11
Targeting Type 2 Diabetes
Schwanstecher, C., & Schwanstecher, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_1 · Cited by 11
On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors
Hinke, S. A., McIntosh, C. H. S., Hoffmann, T., Kühn‐Wache, K., Wagner, L., Bär, J. W., Manhart, S., Wermann, M., Pederson, R. A., & Demuth, H. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1490-b · Cited by 11
GLP-1 secretagogues potential of medicinal plants in management of diabetes
Singh, R., Bhat, G. A., & Sharma, P. K. (2015) · Journal of Pharmacognosy and Phytochemistry · Cited by 10
Efficacy and safety of Jentadueto® (linagliptin plus metformin)
Scheen, A. J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.771631 · Cited by 10
Rebuttal to Deacon and Holst: “Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1” versus “Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective”
Demuth, H., Hinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00753-2 · Cited by 10
Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study
Tang, C. Y. Z., Chua, Y. C., Abdin, E., Subramaniam, M., & Verma, S. K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010137 · Cited by 9
Strategies for prevention and management of second generation antipsychotic-induced metabolic side effects
Marvanová, M. (2013) · Mental Health Clinician · doi:10.9740/mhc.n166832 · Cited by 9
Obesity, metabolic syndrome, and disorders of energy balance
Weiss, R., & Lustig, R. H. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00031-7 · Cited by 9
Glycemic Treatment
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1227 · Cited by 9
Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin
Mizoguchi, M., Takemori, H., Furukawa, S., Ito, M., Asai, M., Morino, H., Miura, T., Yabe, D., & Shibata, T. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0260 · Cited by 8
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Reynolds, J. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4637 · Cited by 8
Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology
Koliaki, C. C., & Doupis, J. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0067-z · Cited by 8
Oral magnesium supplementation modulates hepatic and intestinal expression of some carbohydrate metabolizing genes in type 2 diabetic rats
Fapohunda, O., & Balogun, O. (2019) · International Journal of Molecular Biology Open Access · doi:10.15406/ijmboa.2019.04.00119 · Cited by 8
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Kanozawa, K., Noguchi, Y., Sugahara, S., Nakamura, S., Yamamoto, H., Kaneko, K., Kono, R., Sato, S., Ogawa, T., Hasegawa, H., et al. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-017-1521-7 · Cited by 10
Effect of 5′-adenosine monophosphate-activated protein kinase agonists on insulin and glucose dynamics in experimentally induced insulin dysregulation in horses
Pinnell, E. F., Hostnik, L. D., Watts, M. R., Timko, K. J., Thriffiley, A. A., Stover, M. R., Koenig, L., Gorman, O. M., Toribio, R. E., & Burns, T. A. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16970 · Cited by 7
Rethinking about Metformin: Promising Potentials
Kim, K. (2024) · Korean Journal of Family Medicine · doi:10.4082/kjfm.24.0156 · Cited by 7
Diabetes Mellitus: Disorder of Cellular Dysfunction Due to Lack of Entry into Cell of Glucose. The Most Efficient Fuel for Cellular Function*
Kabadi, U. M. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.113007 · Cited by 7
Different Interactive Effects of Metformin and Acarbose With Dietary Macronutrient Intakes on Patients With Type 2 Diabetes Mellitus: Novel Findings From the MARCH Randomized Trial in China
An, Y., Li, Y., Bian, N., Ding, X., Chang, X., Liu, J., & Wang, G. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.861750 · Cited by 7
Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes
Tajima, A., Hirata, T., Taniguchi, K., Kondo, Y., Kato, S., Saito‐Hori, M., Ishimoto, T., & Yamamoto, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.08.005 · Cited by 7
AMPK Is Involved in the Regulation of Incretin Receptors Expression in Pancreatic Islets under a Low Glucose Concentration
Tajima, K., Shirakawa, J., Togashi, Y., Inoue, H., Sato, K., Orime, K., Ito, Y., Kaji, M., Sakamoto, E., Nakamura, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064633 · Cited by 7
Miniature Short Hairpin RNA Screens to Characterize Antiproliferative Drugs
Kittanakom, S., Arnoldo, A., Brown, K. R., Wallace, I. M., Kunavisarut, T., Torti, D., Heisler, L. E., Surendra, A., Moffat, J., Giaever, G. N., et al. (2013) · G3 Genes Genomes Genetics · doi:10.1534/g3.113.006437 · Cited by 7
Efficacy of metformin on postprandial plasma triglyceride concentration by administration timing in patients with type 2 diabetes mellitus: A randomized cross‐over pilot study
Sato, D., Morino, K., Ogaku, S., Tsuji, A., Nishimura, K., Sekine, O., Ugi, S., & Maegawa, H. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13016 · Cited by 8
Nonalcoholic fatty liver disease in patients with type 2 diabetes
Petunina, N. A., & Эдуардовна, Т. М. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-4-92-95 · Cited by 7
Special Features: Incretin-based therapies in type 2 diabetes mellitus
Cw, C., Jm, E., Chia, C. W., Egan, J. M., correspondence, A., & Egan, J. M. (2014) · Cited by 6
Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes
Henney, A. E., Heague, M., Riley, D. R. J., Hydes, T., Anson, M., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70267 · Cited by 7
Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
Schwartz, S. S., & Katz, A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s65588 · Cited by 7
Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions
Que, L., Qin, W., Shi, Y., Ding, Y., Huang, K., Qian, Z., Huang, B., Zhou, P., & He, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1105767 · Cited by 6
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Green, J., Karen, K., & Cox, M. E. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s10195 · Cited by 7
Mosapride Citrate Increases Postprandial Glucagon-Like Peptide-1, Insulin, and Gene Expression of Sweet Taste Receptors
Maruoka, D., Arai, M., Tanaka, T. Q., Okimoto, K., Oyamada, A., Minemura, S., Tsuboi, M., Matsumura, T., Nakagawa, T., Kanda, T., et al. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3271-7 · Cited by 5
Beyond glycemic control: New guidance on cardio-renal protection
Anastasilakis, A. D., Sternthal, E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.02.004 · Cited by 5
Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
de Boer, N., Gülöksüz, S., van Baal, C. G. C. M., Willebrands, L., Deenik, J., Vinkers, C. H., Rossum, I. W.-V., Zinkstok, J., Wilting, I., Zantvoord, J. B., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-020-02992-4 · Cited by 5
Metformin
Maniar, K., Singh, V., Kumar, D., Moideen, A., Bhattacharyya, R., & Banerjee, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00042-7 · Cited by 5
Regulación de la ingesta alimentaria: una perspectiva clínica
Salvador, J., & Frühbeck, G. (2005) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(05)71040-8 · Cited by 4
Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell
Mulherin, A. J., Oh, A., Kim, H., Grieco, A., Lauffer, L., & Brubaker, P. (2011) · Obesity and metabolism · doi:10.14341/2071-8713-5305 · Cited by 4
Chronic metformin intake improves anaerobic but not aerobic capacity in healthy rats
de Araújo, G. G., LEARSI, S. K., Bastos‐Silva, V. J., Ataíde, T. D. R., & Lima‐Silva, A. E. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0459 · Cited by 4
Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients
Mannucci, E., Pala, L., Monami, M., Vico, L. D., Bardini, G., Dicembrini, I., Ciani, S., Lamanna, C., Marchionni, N., & Rotella, C. M. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346573 · Cited by 4
Self-citation
Differential expression of dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population.
Venkatesham, A., Martha, S., Krishna, D. R., & Pantam, N. (2009) · PubMed · Cited by 4
Lac-Phe mediates the anti-obesity effect of metforminPreprint
Xiao, S., Li, V. L., Lyu, X., Chen, X., Wei, W., Abbasi, F., Knowles, J. W., Deng, S., Tiwari, G., Shi, X., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.02.565321 · Cited by 4
Analytical Techniques for the Determination of Metformin and its Combinations with Oral Antidiabetic Agents in Pharmaceutical Dosage Forms: Combinations with Sulphonylurea Antidiabetic Drugs
Reıd, I. O. A., Osman, S. M., & Bakheet, S. M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i11.6895 · Cited by 3
Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients
Hwang, S. Y., Hsieh, P., Díaz, L. A., Goodman, R. P., Schaefer, E. A. K., Wong, R. J., Luther, J., & Zhang, W. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003162 · Cited by 4
Bariatric Surgery
Ranjit, R., Lapik, I. A., Гаппарова, К. М., & Galchenko, A. V. (2022) · Nutrition Today · doi:10.1097/nt.0000000000000540 · Cited by 4
Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups
Günay, Y., Kı̇şı̇oğlu, S. V., Karakullukçu, S., Tüfekçı̇, D., Demır, A. S., Coşkun, H., Nuhoğlu, İ., Koçak, M., & Ersöz, H. Ö. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230174 · Cited by 3
Profiles of Circulating miRNAs Following Metformin Treatment in Patients with Type 2 Diabetes
Demirsoy, İ. H., Ertural, D. Y., Balcı, Ş., Çınkır, Ü., Sezer, K., Tamer, L., & Aras, N. (2018) · Journal of Medical Biochemistry · doi:10.1515/jomb-2018-0009 · Cited by 3
Metformin-Associated Exacerbation of Chronic Pancreatitis: A Possible Adverse Drug-Disease Interaction
Wadsworth, T. G., Kiester, J., & Thompson, E. G. (2012) · Journal of Pharmacy Technology · doi:10.1177/875512251202800507 · Cited by 3
Metformin as a multi-target modulator of atherosclerosis: integrated regulation of Nrf2/KLF2, mitochondrial homeostasis, inflammation, ferroptosis, and innate immunity
Alanazi, M., Al-Kuraishy, H. M., Mustafa, A. M., Alruwaili, M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag056 · Cited by 2
Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
Minze, M. G., Klein, M. S., & Terrell, B. T. (2013) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s8510 · Cited by 2
Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials
Wang, W., Han, Y., Jiang, X., Shao, J., Zhang, J., Zhou, K., Yang, W., Pan, Q., Nie, Z., & Guo, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16095 · Cited by 2
Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis
Cai, X., Gao, X., Yang, W., & Ji, L. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0124 · Cited by 2
Metformin: Nature′s gift that keeps on giving more!
Balasubramanyam, M. (2014) · Journal of Obesity and Metabolic Research · doi:10.4103/2347-9906.134428 · Cited by 2
Role of Pharmacotherapy in the Treatment of Pediatric Obesity and Its Comorbidities
Kelly, A. S., & Fox, C. K. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-68192-4_35 · Cited by 2
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 2
The effects of a Kenyan antidiabetic plant on insulin homeostasis
Suleiman, K. Y. (2009) · Nelson Mandela University Research Repository · Cited by 2
Effects of metformin on binge‐like ethanol drinking and adenosine monophosphate kinase signaling in inbred high drinking in the dark line 1 mice
Grigsby, K. B., Palacios, J., Chan, A. E., Spencer, S. M., & Ozburn, A. R. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15460 · Cited by 3
Metformin is the lifelong partner in diabetes management: true or false?
Berne, C., & Campbell, I. W. (2011) · The British Journal of Diabetes · doi:10.1177/1474651410397255 · Cited by 1
Fasting and Post Prandial Monitoring of Dipeptidyl Peptidase-IV (DPP-IV) - A Biomarker to Assess Incretin Response in Type-2 Diabetes
Venkatesham, A., Devarakonda, R. K., Reddy, A. R. N., Pantam, N., & Yellu, N. R. (2010) · Stamford Journal of Pharmaceutical Sciences · doi:10.3329/sjps.v2i2.1698 · Cited by 1
Effects of alogliptin benzoate in hemodialysis patients with diabetes
Nakamura, Y., Simizu, T., Fujita, K., Inoue, M., Gotoh, H., Goto, Y., Inagaki, M., & Oguchi, K. (2011) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.45.49 · Cited by 1
Evaluation of Metformin + Sitagliptin versus Metformin + Glibenclamide on Glycemic Control in Iraqis Type 2 Diabetic Patients
Al-Temimi, H. M. A., Al-Shamma, K. J., & M.Alrubaie, S. (2017) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol21iss2pp69-76 · Cited by 1
A Prospective Study on Effectiveness of Sitagliptin with Metformin in Type 2 Diabetic Patients in a Tertiary Care Hospital
Singh, P., Singh, V., Hemnani, T., & Matreja, P. S. (2016) · International Journal of Medical Research Professionals · doi:10.21276/ijmrp.2016.2.3.054 · Cited by 1
Glucagon-Like Peptide 1 and Human Obesity
Anandhakrishnan, A., & Korbonits, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00003-8 · Cited by 1
The Patients at High Risk of Type 2 Diabetes Development
Иванникова, Е. В., & Smirnova, O. M. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-26-50-55 · Cited by 1
Diabesity and the Kidney
Elrggal, M. E., Elkeraie, A. F., Carriazo, S. M., Sawaf, H., Khor, S. Y., Elkeraie, Y., Haddad, I. R., Moustafa, K., & Hassanein, M. M. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070009 · Cited by 1
70 years of metformin use. Success and achievements
Teplova, A. S., Леонидовна, Б. Т., Timofeeva, A. E., & Стегачева, Д. С. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-2-19 · Cited by 1
Evaluación de la expresión del gen GLP-1 (péptido 1 homologo al glucagón) en ratas inducidas a Diabetes Mellitus tipo 2 tratadas con extracto metanólico de Schkuhria pinnata (Canchalagua)
Gutierrez, M. A. Z., Díaz, D. D., Aragón, F. Z., Yáñez, J. A., Arenas Chávez, C., & Vera-Gonzáles, C. (2019) · Revista ECIPeru · doi:10.33017/reveciperu2012.0027/ · Cited by 1
A metformin-monoterápia és a szitagliptin/metformin fix kombináció egyéves perzisztenciája
Simonyi, G., & Ferenci, T. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30423 · Cited by 1
Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome
Janež, A., & Jensterle, M. (2017) · Journal of Diabetes and Obesity · doi:10.15436/2376-0494.17.1246 · Cited by 1
The mechanism of drug interactions of a selected antiarrhythmic drug with metformin, in different animal models
Khan, K. A., Satyanarayana, S., & Kilari, E. K. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902017000400054 · Cited by 1
Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome
Sever, M. J., Ferjan, S., & Janež, A. (2018) · InTech eBooks · doi:10.5772/intechopen.70648 · Cited by 1
Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes
Gallwitz, B. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.23 · Cited by 1
Incretin secretion is not restored by short-term strict glycaemic control in Korean hyperglycaemic patients with type 2 diabetes
Lee, S., Kim, J.-H., Shin, J.-A., Kim, E. S., Cho, J., Ko, S., Yoon, K., & Ahn, Y. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.012
Response to Hinke et al.
Mannucci, E., & Rotella, C. M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1491
Self-citation
Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes
(2010) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s4535
Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells
Kappe, C. (2012) · Figshare
Concomitant Treatment of Type 2 Diabetics with Dipeptidyl Peptidase-4 Inhibitor and Metformin Increases Insulin Sensitivity
Ebeid, A. M. (2012)
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Combination treatment for type 2 diabetes mellitus (T2DM): dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin
Kristin, E. (2017) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci004903201706
Metformin is the lifelong partner in diabetes management: true or false?
Campbell, I. W. (2011)
Management of the metabolic syndrome and glucose intolerance in women with PCOS
Pasquali, R. (2013) · doi:10.2217/ebo.12.271
Specifics of diabetes in old age
Kubíčková, M. (2019) · Interní medicína pro praxi · doi:10.36290/int.2019.034
The Effect of Alogliptin and Metformin Combination Therapy in Type 2 Diabetes: A Pilot Study
Kishimoto (2013) · Journal of Endocrinology and Metabolism · doi:10.4021/jem196e
Dipeptidyl Peptidase-4 Inhibitors
Kim, Y. H., & Cho, Y. M. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_12
Current Awareness
(2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.172
Estudio de la acción antihiperglucemiante de la rosiglitazona en la intolerancia a la glucosa: fase previa de la diabetes mellitus tipo 2
Flores-Saenz, J. L. (2009) · doi:10.24275/uami.m326m1960
Anti-diabetics and glycemic control among type 2 Diabetic patients in out-patients clinics
Mahmood, S. A., Tareq, A., Haithem, Y., Al-Sadi, A. K., Hamood, A., Thabet, M., Saleh, M. A. Q. M., Qasem, M., Saeed, R., & Bamuhill, S. (2019) · University of Aden Journal of Natural and Applied Sciences · doi:10.47372/uajnas.2019.n2.a24
Diabetes Mellitus and Microbiota: Knowledge and Perspectives
Rizzo, G. E., Rizzi, A., Tartaglione, L., Leo, M. L., Viti, L., Leo, M. A. S. D., & Pitocco, D. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-14023-5_7 · Cited by 1
Human microbiome and diabetes
Pizarro, R. R. M., de Guzman, M., Gururagavendiran, S., Mariados, S. W., Deb, S., & Allan, R. B. P. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15435-5.00006-2 · Cited by 1
The potential of metformin in weight loss
Григорьева, И. Н., & Nepomnyashchikh, D. L. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-530
Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome
Damasceno, R. C., Oliveira, F. R., Cândido, A. L., Gomes, K. B., Bizzi, M. F., Azevedo, R. C., Comim, F., Reis, F., & Rocha, A. L. L. (2025) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0451
Caractérisation des effets centraux de la metformine sur des modèles murins sains ou obèses et diabétiques
Rouquet, T. (2015) · theses.fr (ABES) · doi:10.70675/680971a6z149ez4296z9c76z5ee9dfd53ce5
Metformin as a promising therapeutic option for reducing substance withdrawal syndromes: A narrative review
Azadi, S., Fadaei‐kenarsary, M., Sahebi, K., Baneshi, M., Tajbakhsh, A., Niknahad, H., & Negahdaripour, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119553
Glucose acts as a ligand for glucokinase to trigger postprandial secretion of GLP-1
Li, C., Li, M., Yang, H.-Y., Tian, X., Zhang, C., Zhao, L., Wu, J., Zhang, C., Liu, S., Yang, X., et al. (2026) · Vita · doi:10.15302/vita.2026.07.0059 · Cited by 2
Clozapine in Children and Adolescents
Bhatt, A., Miller-Azar, D., Smith, J. R., Cawkwell, P. B., & Clauss, J. A. (2026) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2026.08.004
BindingDB Entry 50021948: Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
BindingDB (2009) · UC San Diego · doi:10.7270/q27w6bx8

Authors: Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M.
Affiliations: University of Florence (IT)
Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author: Rotella, Carlo M.
ORCID: Mannucci, Edoardo
Ognibene, Agostino
Messeri, Gianni
Rotella, Carlo M.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2001-03-01
Volume: 24
Issue: 3
Pages: 489-494
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.24.3.489
OpenAlex: W2157841460
Cited by: 300
References: 26
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 11 · 2018: 17 · 2017: 20 · 2016: 24 · 2015: 12 · 2014: 14 · 2013: 26 · 2012: 18
FWCI: 3.46
Type: journal article
Language: en
Open access: green
www.openaccessrepository.it
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: metformin, glucagon-like peptide-1, leptin, obesity, GLP-1(7-36)amide, dipeptidyl peptidase IV, oral glucose load, hyperinsulinemic-euglycemic clamp, incretin secretion
MeSH terms: Adolescent, Adult, Blood Glucose, Glucagon-Like Peptides, Glucagon, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Peptide Fragments, Peptides, Glucose Clamp Technique, Leptin, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks